Striking citation manipulation in major cancer journals by @baptscc.bsky.social @jabyrnesci.bsky.social David Causeur and @aidybarnett.bsky.social; some with IF over 40. www.pnas.org/doi/10.1073/... Plots from Scancar et al. Can also see this in Impact Inflation (bit.ly/StrainQSS, next posts). 1/4

Show Post

Our 2025 Impact Report looks back at everything our ALK+ #lungcancer community helped make possible, from our biggest national conference yet and growing regional meet-ups to new support, trusted information and stronger advocacy for people with ALK+. www.alkpositive.org.uk/_files/ugd/3... #LCSM

Show Post

🙌 It’s Volunteers’ Week and we want to say a big thank you to everyone who gives their time so generously to volunteer for ALK+ UK and help us better support our ALK+ #lungcancer community. If would like to help us or just find out more, email hello@alkpositive.org.uk. #LCSM

Show Post

Topline results from the phase 3 LAGOON trial showed that lurbinectedin, alone or in combination with irinotecan, missed the primary OS end point in patients with relapsed small cell lung cancer. 📊 Read more ➡️ www.onclive.com/view/topline... #LungCancer #SCLC #ThoracicOncology #lcsm #Oncology

Show Post

Quick 24hrs #whirlwind trip to #Shanghai 🇨🇳🥟🍜 to meet with #lungcancer colleagues 🫁 and friends. Always amazed by the amount and balance of #dynamism and #heritage of the city. #LCSM #drugdevelopment #collaborations

Show Post